While current evidence for SGLT2 inhibition is promising enough to attenuate the impact of this “triple threat”, accruing evidence from ongoing studies should refine our understanding on the place of SGLT2 inhibition in the management of diabetes and its cardio-renal complications (34). The gene discussed is SLC5A2; the disease is diabetes mellitus.